Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 29 July 2005. doi:10.1136/thx.2005.041996
Thorax 2006;61:17-22
Copyright © 2006 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
thx.2005.041996v1
61/1/17    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broekhuizen, R
Right arrow Articles by Schols, A M W J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broekhuizen, R
Right arrow Articles by Schols, A M W J
Topic Collections
Right arrowRelevant Article

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Raised CRP levels mark metabolic and functional impairment in advanced COPD

R Broekhuizen1, E F M Wouters1, E C Creutzberg2, A M W J Schols1

1 Department of Respiratory Medicine, University Hospital Maastricht, The Netherlands
2 Asthma Centre Hornerheide, Horn, The Netherlands

Correspondence to:
Correspondence to:
Dr R Broekhuizen
Department of Respiratory Medicine, University Hospital Maastricht, P O Box 5800, 6202 AZ Maastricht, The Netherlands; r.broekhuizen{at}pul.unimaas.nl

Background: C-reactive protein (CRP) is often used as a clinical marker of acute systemic inflammation. Since low grade inflammation is evident in chronic diseases such as chronic obstructive pulmonary disease (COPD), new methods have been developed to enhance the sensitivity of CRP assays in the lower range. A study was undertaken to investigate the discriminative value of high sensitivity CRP in COPD with respect to markers of local and systemic impairment, disability, and handicap.

Methods: Plasma CRP levels, interleukin 6 (IL-6) levels, body composition, resting energy expenditure (REE), exercise capacity, health status, and lung function were determined in 102 patients with clinically stable COPD (GOLD stage II–IV). The cut off point for normal versus raised CRP levels was 4.21 mg/l.

Results: CRP levels were raised in 48 of 102 patients. In these patients, IL-6 (p<0.001) and REE (adjusted for fat-free mass, p = 0.002) were higher while maximal (p = 0.040) and submaximal exercise capacity (p = 0.017) and 6 minute walking distance (p = 0.014) were lower. The SGRQ symptom score (p = 0.003) was lower in patients with raised CRP levels, as were post-bronchodilator FEV1 (p = 0.031) and reversibility (p = 0.001). Regression analysis also showed that, when adjusted for FEV1, age and sex, CRP was a significant predictor for body mass index (p = 0.044) and fat mass index (p = 0.016).

Conclusions: High sensitivity CRP is a marker for impaired energy metabolism, functional capacity, and distress due to respiratory symptoms in COPD.


Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FFMI, fat-free mass index; FM, fat mass; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PaO2, arterial oxygen tension; PaCO2, carbon dioxide tension; RER, respiratory exchange ratio; TLCO, carbon monoxide transfer factor; V·E, ventilation; V·O2, oxygen consumption; V·CO2, carbon dioxide production

Keywords: C-reactive protein; chronic obstructive pulmonary disease; systemic inflammation; exercise capacity; health status; interleukin 6


Relevant Article

Airwaves
Wisia Wedzicha
Thorax 2006 61: 1. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
W. MacNee, J. Maclay, and D. McAllister
Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2008; 5(8): 824 - 833.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
F M E Franssen, D E O'Donnell, G H Goossens, E E Blaak, and A M W J Schols
Obesity and the lung: 5 {middle dot} Obesity and COPD
Thorax, December 1, 2008; 63(12): 1110 - 1117.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
B. K. Butland, D. P. Strachan, and A. R. Rudnicka
C-reactive protein, obesity, atopy and asthma symptoms in middle-aged adults
Eur. Respir. J., July 1, 2008; 32(1): 77 - 84.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. K. Quint, R. Baghai-Ravary, G. C. Donaldson, and J. A. Wedzicha
Relationship between depression and exacerbations in COPD
Eur. Respir. J., July 1, 2008; 32(1): 53 - 60.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. F. Chung and I. M. Adcock
Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction
Eur. Respir. J., June 1, 2008; 31(6): 1334 - 1356.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz
Cardiac Disease in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
W. M. Chatila, B. M. Thomashow, O. A. Minai, G. J. Criner, and B. J. Make
Comorbidities in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. Watz, B. Waschki, C. Boehme, M. Claussen, T. Meyer, and H. Magnussen
Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity: A Cross-sectional Study
Am. J. Respir. Crit. Care Med., April 1, 2008; 177(7): 743 - 751.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D. D Sin and W D. Reid
Is inflammation good, bad or irrelevant for skeletal muscles in COPD?
Thorax, February 1, 2008; 63(2): 95 - 96.
[Full Text] [PDF]


Home page
ThoraxHome page
R. J Hancox, R. Poulton, J. M Greene, S. Filsell, C. R McLachlan, F. Rasmussen, D R. Taylor, M. J A Williams, A. Williamson, and M. R Sears
Systemic inflammation and lung function in young adults
Thorax, December 1, 2007; 62(12): 1064 - 1068.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Respiratory DiseaseHome page
J. Tkac, S. F. P. Man, and D. D. Sin
Review: Systemic consequences of COPD
Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 47 - 59.
[Abstract] [PDF]


Home page
ERRHome page
S. I. Rennard
Inflammation in COPD: a link to systemic comorbidities
Eur. Respir. Rev., September 1, 2007; 16(105): 91 - 97.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
V. Pinto-Plata, J. Toso, K. Lee, D. Park, J. Bilello, H. Mullerova, M. M De Souza, R. Vessey, and B. Celli
Profiling serum biomarkers in patients with COPD: associations with clinical parameters
Thorax, July 1, 2007; 62(7): 595 - 601.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri
Update in Chronic Obstructive Pulmonary Disease 2006
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1222 - 1232.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Sabit, C. E. Bolton, P. H. Edwards, R. J. Pettit, W. D. Evans, C. M. McEniery, I. B. Wilkinson, J. R. Cockcroft, and D. J. Shale
Arterial Stiffness and Osteoporosis in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1259 - 1265.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. A. C. Ottenheijm, L. M. A. Heunks, and P. N. R. Dekhuijzen
Diaphragm Muscle Fiber Dysfunction in Chronic Obstructive Pulmonary Disease: Toward a Pathophysiological Concept
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1233 - 1240.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren
Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD
Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Dahl, J. Vestbo, P. Lange, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 250 - 255.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. D. Sin, N. R. Anthonisen, J. B. Soriano, and A. G. Agusti
Mortality in COPD: role of comorbidities
Eur. Respir. J., December 1, 2006; 28(6): 1245 - 1257.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. R. Hurst, G. C. Donaldson, W. R. Perera, T. M. A. Wilkinson, J. A. Bilello, G. W. Hagan, R. S. Vessey, and J. A. Wedzicha
Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 867 - 874.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Pelkonen, I.-L. Notkola, A. Nissinen, H. Tukiainen, and H. Koskela
Thirty-Year Cumulative Incidence of Chronic Bronchitis and COPD in Relation to 30-Year Pulmonary Function and 40-Year Mortality: A Follow-up in Middle-Aged Rural Men.
Chest, October 1, 2006; 130(4): 1129 - 1137.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. E. Meyer, S. J. Kovacs, A. A. Ehsani, S. Klein, J. O. Holloszy, and L. Fontana
Reply
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 848 - 848.
[Full Text] [PDF]


Home page
Eur Respir JHome page
G. P. Anderson
COPD, asthma and C-reactive protein.
Eur. Respir. J., May 1, 2006; 27(5): 874 - 876.
[Full Text] [PDF]


Home page
Eur Respir JHome page
E. F. M. Wouters
The systemic face of airway diseases: the role of C-reactive protein.
Eur. Respir. J., May 1, 2006; 27(5): 877 - 879.
[Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
E. F. M. Wouters
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. P. de Torres, E. Cordoba-Lanus, C. Lopez-Aguilar, M. Muros de Fuentes, A. Montejo de Garcini, A. Aguirre-Jaime, B. R. Celli, and C. Casanova
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Eur. Respir. J., May 1, 2006; 27(5): 902 - 907.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D D Sin and S F P Man
Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?
Thorax, January 1, 2006; 61(1): 1 - 3.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & British Thoracic Society